Director Declaration
Oxford Biomedica PLC announced that Peter Soelkner, Vice Chair and Independent Non-Executive Director, has been appointed as a Non-Executive Director of Stevanato Group S.p.A., a NASDAQ listed company, effective May 26, 2026. This appointment is in accordance with UK Listing Rules 6.4.9R.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 27 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.